PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 137 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 0.37 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $70,000 | -58.1% | 18,385 | -44.0% | 0.00% | 0.0% |
| Q4 2019 | $167,000 | -6.7% | 32,852 | -7.4% | 0.00% | 0.0% |
| Q3 2019 | $179,000 | -19.7% | 35,485 | -1.7% | 0.00% | 0.0% |
| Q2 2019 | $223,000 | +19.3% | 36,100 | -10.5% | 0.00% | 0.0% |
| Q1 2019 | $187,000 | +11.3% | 40,327 | +1.0% | 0.00% | 0.0% |
| Q4 2018 | $168,000 | -42.9% | 39,919 | -14.8% | 0.00% | -50.0% |
| Q3 2018 | $294,000 | -15.3% | 46,878 | +8.7% | 0.00% | 0.0% |
| Q2 2018 | $347,000 | +6.4% | 43,131 | -1.3% | 0.00% | 0.0% |
| Q1 2018 | $326,000 | +8.7% | 43,709 | -13.4% | 0.00% | 0.0% |
| Q4 2017 | $300,000 | -11.0% | 50,496 | +10.2% | 0.00% | -33.3% |
| Q3 2017 | $337,000 | +14.6% | 45,810 | +5.7% | 0.00% | 0.0% |
| Q2 2017 | $294,000 | -33.8% | 43,343 | -7.8% | 0.00% | -40.0% |
| Q1 2017 | $444,000 | -10.5% | 47,031 | -18.1% | 0.01% | 0.0% |
| Q4 2016 | $496,000 | +53.6% | 57,459 | +12.6% | 0.01% | 0.0% |
| Q3 2016 | $323,000 | +26.2% | 51,014 | -15.8% | 0.01% | +66.7% |
| Q2 2016 | $256,000 | -2.3% | 60,586 | +0.6% | 0.00% | -25.0% |
| Q1 2016 | $262,000 | -35.5% | 60,199 | -9.2% | 0.00% | -20.0% |
| Q4 2015 | $406,000 | +18.7% | 66,276 | +10.8% | 0.01% | 0.0% |
| Q3 2015 | $342,000 | -28.9% | 59,795 | -7.2% | 0.01% | -28.6% |
| Q2 2015 | $481,000 | +15.9% | 64,436 | -7.3% | 0.01% | +40.0% |
| Q1 2015 | $415,000 | -9.6% | 69,478 | +14.3% | 0.01% | 0.0% |
| Q4 2014 | $459,000 | +39.9% | 60,772 | -3.9% | 0.01% | +25.0% |
| Q3 2014 | $328,000 | +0.3% | 63,222 | -16.6% | 0.00% | 0.0% |
| Q2 2014 | $327,000 | -34.3% | 75,810 | -37.7% | 0.00% | -33.3% |
| Q1 2014 | $498,000 | +200.0% | 121,652 | +290.4% | 0.01% | +200.0% |
| Q4 2013 | $166,000 | -44.1% | 31,160 | -47.2% | 0.00% | -71.4% |
| Q3 2013 | $297,000 | +68.8% | 59,015 | +49.6% | 0.01% | +133.3% |
| Q2 2013 | $176,000 | – | 39,452 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
| Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
| FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
| J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
| EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
| Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |